Fat intake interacts with polymorphisms of Caspase9, FasLigand and PPARgamma apoptotic genes in modulating Crohn's disease activity

Clinical Nutrition

Volumn 29, Issue 6, 2010, Pages 819-823

  Ferreira, Paula ^a   Cravo, Marília ^b   Guerreiro, Catarina Sousa ^a,c   Tavares, Lourdes ^d   Santos, Paula Moura ^d   Brito, Miguel ^a  

^a INSTITUTO POLITÉCNICO DE LISBOA   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; FAS LIGAND; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SATURATED FATTY ACID;

ADULT; APOPTOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; LIPID DIET; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AGED; CASE-CONTROL STUDIES; CASPASE 9; CROHN DISEASE; DIET; DIETARY FATS; FAS LIGAND PROTEIN; FATTY ACIDS, UNSATURATED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; REGRESSION ANALYSIS;

EID: 78649870242     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.06.008     Document Type: Article

References (24)

1. Ahmad T., Armuzzi A., Bunce M., Mulcahy-Hawes K., Marshall S.E., Orchard T.R., et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002, 122:854-866.
2. Satsangi J., Morecroft J., Shah N.B., Nimmo E. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003, 17(1):3-18.
3. Louis E., Satsangi J., Roussomoustakaki M., Parkes M., Fanning G., Welsh K., et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996, 39:705-710.
4. Souza H.S., Tortori C.J., Castelo-Branco M.T., Carvalho A.T., Margallo V.S., Delgado C.F., et al. Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways. Int J Colorectal Dis 2005, 20:277-286.
5. Teitelbaum J.E., Walker W.A. Review: the role of omega 3 fatty acids in intestinal inflammation. J Nutr Biochem 2001, 12:21-32.
6. Gassull M.A., Fernández-Bañares F., Cabré E., Papo M., Giaffer M.H., Sánchez-Lombraña J.L., et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomized multicentre European trial. Gut 2002, 51:164-168.
7. Mañé J., Pedrosa E., Lorén V., Ojanguren I., Fluvià L., Cabré E., et al. Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. J Nutr 2009, 139(3):603-610.
8. Llor X., Pons E., Roca A., Alvarez M., Mañé J., Fernández-Bañares F., et al. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutr 2003, 22(1):71-79.
9. Sadeghi S., Wallace F.A., Calder P.C. Dietary lipids modify the cytokine response to bacterial lipopolysaccharide in mice. Immunology 1999, 96:404-410.
10. Grimble R., Howell W., O'Reilly G., Turner S., Markovic O., Hirrell S., et al. The ability of fish oil to suppress tumour necrosis factor x production by peripheral blood monuclear cells in healthy men is associated with polymorphisms in genes that influence tumour necrosis factor α production. Am J Clin Nutr 2002, 76:454-459.
11. Guerreiro C.S., Ferreira P., Tavares L., Santos P.M., Neves M., Brito M., et al. Fatty acids, IL-6 and TNF-α polymorphisms: an example of nutrigenetics in Crohn's disease. Am J Gastroenterol 2009, 104(9):2241-2249.
12. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24(170):2-6.
13. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1(8167):514.
14. Sambrook J., Maniatis T., Fritsch E.F. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 2nd ed.
15. Lopes C.M. Reprodutibilidade e validação do questionário semiquantitativo de frequência alimentar. In: alimentação e Enfarte agudo do miocárdio: estudo de caso-controlo de base comunitária. Tese de Doutoramento Porto 2000;pp. 78-115.
16. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., van Schuerbeek N., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005, 22:613-626.
17. Pischon T., Hankinson S.E., Hotamisligil G.S., Rifai N., Willett W.C., Rimm E.B., et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003, 108:155-160.
18. Srivastava R. Apoptosis, cell signaling, and human diseases - molecular mechanisms 2007, vol. 2. Humana Press Inc., Totowa, New Jersey.
19. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.M., Saladin R., et al. The organization, promoter analysis, and expression of the Human PPARg Gene. J Biol Chem 1997, 272(30):18779-18789.
20. Debril M.B., Renaud J.P., Fajas L., Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor γ. J Mol Med 2001, 79:30-47.
21. Gong Z., Xie D., Deng Z., Bostick R.M., Muga S.J., Hurley T.G., et al. The PPARg Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis 2005, 26(3):579-585.
22. Xia B., Yu Y.H., Guo Q.S., Li X.Y., Jiang L., Li J. Association of Fas-670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol 2005, 11(3):415-417.
23. Bu P., Keshavarzian A., Stone D.D., Liu J., Le P.T., Fisher S., et al. Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J Immunol 2001, 166:6399-6403.
24. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C., et al. A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters FasLigand expression: a candidate background gene in African American systemic Lupus Erythematosus patients. J Immunol 2003, 170:132-138.